At a glance
ClinicalIndex Comparison Record- ✓Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular/diffuse large cell non-Hodgkin's lymphoma, refractory to or intolerant of established therapy
- ✓Tumors must express Rb (retinoblastoma protein)
- ✓ECOG performance status 0, 1, or 2
- ✓Adequate blood cell counts, kidney function, and liver function
- ✕Prior stem cell or bone marrow transplant
- ✕Uncontrolled infection, unstable or severe intercurrent medical condition, or current drug or alcohol abuse
- ✕Active or unstable cardiac disease or history of myocardial infarction within 6 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
In Brief
A Phase 1 clinical trial evaluating PD-0332991 for Neoplasms and Lymphoma, Non-Hodgkin. Completed, enrolled 74 participants across 4 sites.
Detailed Summary
PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.
Study Details
Timeline
Interventions
Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily